ALVO SDB Stock Overview

Through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. More details

ALVO SDB fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	5/6
Past Performance	2/6
Financial Health	1/6
Dividends	0/6

Rewards

Trading at 81.7% below our estimate of its fair value

Earnings are forecast to grow 49.39% per year

Became profitable this year

Risk Analysis

Debt is not well covered by operating cash flow

Negative shareholders equity

High level of non-cash earnings

Shares are highly illiquid

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Alvotech Competitors

Price History & Performance

Summary of share price highs, lows and changes for Alvotech
Historical stock prices
Current Share Price	US$94.45
52 Week High	US$100.48
52 Week Low	US$90.51
Beta	-0.022
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-3.92%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	ALVO SDB	SE Biotechs	SE Market
7D	n/a	3.9%	0.4%
1Y	n/a	-0.9%	-3.7%

Return vs Industry: Insufficient data to determine how ALVO SDB performed against the Swedish Biotechs industry.

Return vs Market: Insufficient data to determine how ALVO SDB performed against the Swedish Market.

Price Volatility

Is ALVO SDB's price volatile compared to industry and market?
ALVO SDB volatility
ALVO SDB Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.9%
Market Average Movement	6.8%
10% most volatile stocks in SE Market	13.7%
10% least volatile stocks in SE Market	4.2%

Stable Share Price: ALVO SDB's share price has been volatile over the past 3 months compared to the Swedish market.

Volatility Over Time: Insufficient data to determine ALVO SDB's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2013	1,012	Robert Wessman	www.alvotech.com

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company’s lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.

Alvotech Fundamentals Summary

How do Alvotech's earnings and revenue compare to its market cap?
ALVO SDB fundamental statistics
Market cap	SEK 28.27b
Earnings (TTM)	SEK 924.73m
Revenue (TTM)	SEK 5.63b

31.8x

P/E Ratio

5.2x

P/S Ratio

Is ALVO SDB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALVO SDB income statement (TTM)
Revenue	US$587.89m
Cost of Revenue	US$230.80m
Gross Profit	US$357.09m
Other Expenses	US$260.55m
Earnings	US$96.55m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

Aug 13, 2025

Earnings per share (EPS)	0.32
Gross Margin	60.74%
Net Profit Margin	16.42%
Debt/Equity Ratio	-362.8%

How did ALVO SDB perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/21 23:20
End of Day Share Price	2025/05/21 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alvotech is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Andrew Baum	Citigroup Inc
Peter Verdult	Citigroup Inc
Emmanuel Papadakis	Deutsche Bank